The authors have no conflict of interest.
Phenotypic Effects of Biglycan Deficiency Are Linked to Collagen Fibril Abnormalities, Are Synergized by Decorin Deficiency, and Mimic Ehlers-Danlos-Like Changes in Bone and Other Connective Tissues†
Article first published online: 1 JUL 2002
Copyright © 2002 ASBMR
Journal of Bone and Mineral Research
Volume 17, Issue 7, pages 1180–1189, July 2002
How to Cite
Corsi, A., Xu, T., Chen, X.-D., Boyde, A., Liang, J., Mankani, M., Sommer, B., Iozzo, R. V., Eichstetter, I., Robey, P. G., Bianco, P. and Young, M. F. (2002), Phenotypic Effects of Biglycan Deficiency Are Linked to Collagen Fibril Abnormalities, Are Synergized by Decorin Deficiency, and Mimic Ehlers-Danlos-Like Changes in Bone and Other Connective Tissues. J Bone Miner Res, 17: 1180–1189. doi: 10.1359/jbmr.2002.17.7.1180
- Issue published online: 2 DEC 2009
- Article first published online: 1 JUL 2002
- Manuscript Accepted: 6 FEB 2002
- Manuscript Revised: 25 JAN 2002
- Manuscript Received: 23 OCT 2001
- collagen fibrils;
Decorin (dcn) and biglycan (bgn), two members of the family of small leucine-rich proteoglycans (SLRPs), are the predominant proteoglycans expressed in skin and bone, respectively. Targeted disruption of the dcn gene results in skin laxity and fragility, whereas disruption of the bgn gene results in reduced skeletal growth and bone mass leading to generalized osteopenia, particularly in older animals. Here, we report that bgn deficiency leads to structural abnormality in collagen fibrils in bone, dermis, and tendon, and to a “subclinical” cutaneous phenotype with thinning of the dermis but without overt skin fragility. A comparative ultrastructural study of different tissues from bgn- and dcn-deficient mice revealed that bgn and dcn deficiency have similar effects on collagen fibril structure in the dermis but not in bone. Ultrastructural and phenotypic analysis of newly generated bgn/dcn double-knockout (KO) mice revealed that the effects of dcn and bgn deficiency are additive in the dermis and synergistic in bone. Severe skin fragility and marked osteopenia characterize the phenotype of double-KO animals in which progeroid changes are observed also in the skin. Ultrastructural analysis of bone collagen fibrils in bone of double-KO mice reveals a complete loss of the basic fibril geometry with the emergence of marked “serrated fibril” morphology. The phenotype of the double-KO animal mimics directly the rare progeroid variant of human Ehlers-Danlos syndrome (EDS), in which skin fragility, progeroid changes in the skin (reduced hypodermis), and osteopenia concur as a result of impaired glycosaminoglycan (GAG) linking to bgn and dcn core proteins. Our data show that changes in collagen fibril morphology reminiscent of those occurring in the varied spectrum of human EDS are induced by both bgn deficiency and dcn deficiency in mice. The effects of an individual SLRP deficiency are tissue specific, and the expression of a gross phenotype depends on multiple variables including level of expression of individual SLRPs in different tissues and synergisms between different SLRPs (and likely other macromolecules) in determining matrix structure and functional properties.
DECORIN (dcn) and biglycan (bgn) belong to the family of secreted small leucine-rich proteoglycans (SLRPs).(1–4) This family includes at least 12 different molecules that can be divided into three distinct subfamilies based on similarities in amino acid sequences and gene organization. Their core proteins are composed of tandemly linked repeats of an ∼25 amino acid leucine-rich sequence to which different glycosaminoglycan (GAG) chains are attached. However, alternative post-translational modifications of certain SLRP members also may result in the biosynthesis of mature proteins more properly referred to as glycoproteins rather than proteoglycans.(3) To date, no primary genetic defects in either DCN or BGN have been reported in humans. However, steady-state levels of biglycan mRNA and protein are altered in cells derived from patients with anomalies of the X chromosome, where the biglycan gene is located.(5)
In most tissues, SLRPs are thought to regulate extracellular matrix structure and organization. They are postulated also to regulate cell growth and differentiation, mainly by modulating local storage and/or availability of different growth factors including transforming growth factor (TGF) β(4,6,7) and by interacting with receptor tyrosine kinases.(8) Various members of the SLRP family are known to interact directly with fibrillar collagen, thereby modulating fibril formation, growth, and morphology(9–16) in vitro.
However, detailed functions of each SLRP in vivo remain to be clarified. Differences in their interaction with collagens, GAG content, and, in particular, the different patterns of expression in different tissues may imply diverse, tissue-specific roles for each SLRP.(4,17) Some degree of tissue specificity indeed has been highlighted by the development of mouse models carrying targeted null mutations of individual SLRP genes. A phenotype characterized by skin laxity and fragility, reminiscent of certain human Ehlers-Danlos syndromes (EDSs), was observed in mice deficient in decorin, the most abundant SLRP in skin.(18) Likewise, mice deficient in lumican (an SLRP enriched in the cornea) develop corneal opacity.(19) In contrast, a skeletal phenotype characterized by growth failure, reduced bone formation, and osteopenia has been described recently in bgn-deficient mice.(20) Ultrastructural anomalies of dermal and corneal collagen fibrils have been observed in dcn and lumican-deficient mice but have not been reported in bgn-deficient animals.
The studies described here were designed to learn more about the role of bgn in connective tissue matrices, including nonskeletal tissues in which macroscopic abnormalities are not observed in the bgn-deficient mice. Toward this goal, we examined the ultrastructural morphology of collagenous matrices in bgn-deficient mice in comparison with dcn-deficient and wild-type (WT) animals. To further investigate the potential interplay of bgn and dcn in bone and other connective tissues, we generated bgn and dcn double-deficient mice. This allowed us to investigate the effects of biglycan deficiency in a decorin-deficient as well as in a decorin-sufficient background.
MATERIALS AND METHODS
Animals and tissues
All experiments using mice were performed under an institutionally approved protocol for the use of animals in research (NIDCR-IRP-98-058). The dcn- and bgn-deficient animals were generated as described.(18,20) Animals deficient in both dcn and bgn were generated as detailed in the following section. Male mice were used in this study. Throughout the text we have designated mice with genotype dcn−/− as dcn deficient or knockout (KO); bgn−/0 as bgn deficient or KO; dcn−/−, bgn−/0 as double-KO; and bgn+/0, dcn+/+ as WT. Data presented were from littermates from the F2 generation.
Generation of bgn/dcn-deficient mice
Heterozygous dcn-deficient (−/+) male mice were crossed with homozygous bgn-deficient (−/−) female mice. F1 male mice with the genotype dcn (−/+) bgn (−/0) (designated as such because there is no allele on the Y chromosome) were bred to female mice with the genotype dcn (−/+) bgn (−/+) to generate F2 animals. Mice deficient in both bgn and dcn were identified by polymerase chain reaction (PCR) using DNA extracted from a 3-mm tail biopsy specimen with the Highpure PCR Template Preparation Kit (Boehringer Mannheim, Indianapolis, IN, USA). To identify the normal and targeted dcn alleles, three oligonucleotide primers were used: a forward primer corresponding to the 5′ end of exon two (5′-ccttctggcacaagtctcttgg-3′; accession no. NM 007833, bases 255-276) and a reverse primer encoding either the 3′ end of exon two (5′-tcgaagatgacactggcatcgg-3′; accession no. NM007833, reverse and complement of bases 324-405) or a primer with sequences within the phosphoglycerate kinase (PGK) promoter (5′-tggatgtggaatgtgtgcgagg-3′) of the targeted allele (Genbank accession no. AF090454, bases 1901-1922). Ten microliters of purified DNA (10-100 ng) were used as a template for the PCR reactions, which contained 2 ng/μl of each primer, 0.2 mM of deoxynucleoside triphosphate (dNTP) and a 1× PCR buffer supplemented with 1.5 mM of MgCl (Applied Biosystems, Philips, Eindhoven, The Netherlands). After incubation of the reaction mixture at 95°C, a 0.5-μl aliquot of Amplitaq gold (Applied Biosystems) was added to a total volume (TV) of 50 μl and the reaction was allowed to proceed for 35 cycles at 95°C for 1 minute, 57°C for 20 s, and 72°C for 30 s. PCR products were resolved by electrophoresis through 1.8% agarose gels, yielding bands that were 161 bp for WT and 238 bp for targeted dcn alleles. Genotyping the bgn alleles used a similar strategy. In addition to the PGK primer described previously, a forward primer corresponding to the 5′ end of exon two (5′-caggaacattgaccatg-3′; Genbank accession no. NM007542, bases 126-142) and a reverse primer corresponding to the 3′ end of exon two (5′-gaaaggacacatggcactgaag-3′; Genbank accession no. NM007542, reverse and complement of bases 316-337) were used as described previously. Diagnostic bands of 212 bp and 310 bp represent the WT and targeted bgn allele, respectively. Out of 150 mice tested, only 5 were double KO; this is considerably lower (∼3.3%) than expected for Mendelian inheritance (12.5%) using this breeding regime.
X-ray studies and histology
Mice were killed at 2-5 months and hard tissues (femur and tibia) were dissected and soft tissues were removed. Femora were radiographed using a Faxitron MX-20 Specimen Radiography System (Faxitron X-ray Corp., Wheeling, IL, USA) at energy of 30 kV for 30 s. The images were captured with Eastman Kodak Co. X-OMAT TL (Eastman Kodak Co., Rochester, NY, USA). Both soft (ventral skin and tail tendon) and hard tissue samples were fixed with fresh 4% formalin in 0.1 M of phosphate buffer, pH 7.2, for 16 h at 4°C. After washing, tissues were stored in 70% ethanol before embedding and processing. Samples from ventral skin and tail were embedded routinely in paraffin. Five-micrometer-thick paraffin sections were stained with hematoxylin-eosin or Mallory's trichrome. The right femora and tibias were divided into proximal and distal halves and embedded undecalcified in glycol-methacrylate (GMA).(21) Three-micrometer-thick GMA sections were stained with May Grunwald-Giemsa or von Kossa.
Histomorphometry was performed with a semiautomatic image analyzer (IAS 2000; Delta System, Rome, Italy). Three animals of each strain were used to measure dermal thickness (μm) and bone volume/TV (BV/TV, %). Dermal thickness was established by measuring five distances from the dermo-epidermal junction to the lower end of the dermis in ten adjacent fields by objective 10× (on screen area 0.21 mm2). BV/TV was determined as described previously.(20) The data are expressed as mean ± SD.
Transmission electron microscopy
Samples obtained from the ventral skin, tail tendon, and the left tibias of 2-month-old mice of each strain were subjected to transmission electron microscopy (TEM) analysis. Before embedding, the tibia was divided into halves; the proximal half was left undecalcified and the distal half was decalcified in neutral buffered 10% EDTA. After washing in PBS, the samples were postfixed for 1 h at 4°C with 1% osmium tetroxide in cacodylate buffer, rinsed in water, dehydrated through graded ethanol solutions, transferred to propylene oxide, and embedded in epoxy resin (Araldite). Semithin sections were stained with Azur II-Methylene Blue and examined with a light microscope to select appropriate fields; ultrathin sections were contrasted with uranyl acetate and lead citrate and examined with a CM 10 Philips electron microscope (KE Electronics, Tofts, UK).
Multiple micrographs of cross-sections of dermal, tail tendon, and nonmineralized-bone collagen fibrils were chosen randomly and used for morphometry. Mean diameter, range, and frequency distribution profiles were obtained by measuring manually the biggest diameter of 2000 collagen fibrils from each tissue.
Scanning electron microscopy
Dehydrated samples from the left femora were embedded in polymethyl methacrylate (PMMA) and the blocks were trimmed, micromilled to a ≤0.1-μm relief, prepared, polished, and carbon-coated as described.(22) Quantitative backscattered electron (qBSE) imaging and the density of mineralization of the bone tissue were evaluated in a digital scanning electron microscope (SEM) (Zeiss DSM 962 with Kontron IBAS external control computer) operating under standardized conditions.(23–25)
Biglycan deficiency induces changes in collagen fibril morphology
TEM studies of skin, tendon, and bone samples of bgn-deficient mice (Fig. 1) revealed the occurrence of a host of collagen fibril anomalies, including changes both in fibril size and in fibril shape. In all tissues, a marked variability of fibril diameter and the frequent occurrence of fibrils with an irregular cross-sectional profile (with a ragged or notched contour) were observed. Longitudinal sections of collagen fibrils also showed the occurrence of marked diameter variability along an individual fibril axis (so-called twisted fibrils) in mutant mice.
Collagen abnormalities induced by biglycan or decorin deficiency are different in different tissues
On the whole, the collagen fibril abnormalities observed in bgn-deficient mice were qualitatively similar to those previously described in the skin and tendon of decorin-deficient mice.(18) However, the overall phenotypes resulting from either decorin or biglycan deficiency are quite distinct (skin fragility vs. osteopenia(18,20)). Therefore, we comparatively analyzed fibril morphology, average diameter, range, and frequency distribution in skin, tail tendon, and bone from the two strains of mutant mice (Fig. 2).
Dermal collagen fibrils of WT animals had an average diameter of 62.07 nm with a range of 20-148.59 nm. Both bgn deficiency and dcn deficiency produced, in the dermis, an increase in fibril average diameter (bgn, 104.14 nm; dcn, 87.6 nm) and range (bgn, 21.05-316.35 nm; dcn, 17.14-224.51 nm) compared with WT animals. Fibrils with an unusually high diameter were apparent both in bgn- and dcn-deficient animals. The larger fibrils often exhibited an irregular cross-sectional profile. Consequently, at the TEM level, the effect of bgn deficiency (wider-size range and higher average diameter of collagen fibrils) was similar to the effect of dcn deficiency.
The tail tendon of WT animals contained two discrete main populations of fibrils, (30-60 nm and 100-150 nm in diameter, respectively) resulting in a typical bimodal profile of frequency distribution. Both in the bgn-deficient animals and in the dcn-deficient animals, fibril diameter exhibited instead a unimodal frequency distribution because of a relative decrease in number of larger fibrils and a relative increase in number of smaller fibrils. The fibril size range was increased compared with WT animals (12.9-321.76 nm) both in the bgn-deficient animals (12.9-435.08 nm) and in the dcn-deficient animals (17.39-452.2 nm), reflecting the occurrence of unusually large fibrils. The average diameter of tendon collagen fibrils was reduced in the bgn-deficient mice (107.4 nm) and increased in the dcn-deficient mice (127.74 nm), compared with WT animals (118.1 nm).
In bone from WT animals, collagen fibrils had an average diameter of 29.46 nm with a range of 10.26-66.66 nm. Both bgn and dcn deficiency had an effect on fibril structure and size. However, the effect was not the same in either case. In the bgn-deficient mice, both the fibril average diameter (32.52 nm) and the range (10.26-84.21 nm) were increased compared with WT mice. In the decorin-deficient mice, conversely, both the average diameter (25.9 nm) and the size range (10.26-59.64 nm) were decreased compared with WT mice. Irregular cross-sectional profiles were more obvious in the bgn-deficient mice.
Bgn deficiency and dcn deficiency induce subtle phenotypes in skin and bone, respectively
Because collagen fibril abnormalities observed in the skin of bgn-deficient mice were similar to those observed in dcn-deficient mice, we investigated the potential occurrence of a gross or histological cutaneous phenotype in bgn-deficient mice. In 2-month-old dcn-deficient mice, simple manual stretching was sufficient to produce a rupture of the skin (dermatosparaxis), as previously reported.(18) Similar maneuvers never produced any tearing of the skin in the bgn-deficient mice or in WT animals. However, histological evaluation of skin samples from both strains of mutant mice showed a similar reduction in the thickness of the dermis compared with WT animals (Fig. 3). We concluded from these observations that collagen anomalies are reflected in an overt dermatosparaxis-like phenotype in the dcn-deficient, bgn-sufficient mice, but only in a subtle, “subclinical” cutaneous phenotype in bgn-deficient, dcn-sufficient mice.
Because dcn deficiency induced a detectable change in collagen fibril size and shape in bone, we asked whether a subtle skeletal phenotype could be shown in dcn-deficient mice. No reduction in skeletal mass similar to the previously reported skeletal phenotype of bgn-deficient mice was observed in the dcn-deficient mice on by X-ray analysis, histological examination, or histomorphometric assessment of trabecular bone mass (BV/TV%, Fig. 4). Thus, we concluded that decorin deficiency only induced an EM-detectable phenotype in bone, with no expression at the histological or gross level.
Decorin deficiency enhances skeletal and extraskeletal effects of biglycan deficiency
To investigate the potential skeletal and extraskeletal effects of biglycan deficiency in a decorin-deficient background (and vice versa), we generated bgn/dcn double-KO animals. A dermatosparaxis-like gross phenotype was prominent in the double mutant, with tearing of the coat occurring even after gentle stretching (Fig. 5). Ruptures were consistently wider than in the dcn-deficient mice.
Histologically, the skin of double-deficient animals showed a thinned dermis, compared with WT animals, like bgn- and dcn-deficient mice, and showed, in addition, two specific qualitative differences. The texture of dermal collagen was obviously looser, with wide spaces separating collagen bundles. In addition, the hypodermis was uniformly atrophic. Ultrastructural analysis of the dermal collagen showed that double-SLRP deficiency resulted in a more marked variability in fibril size (reflected in a wider range of fibril diameter: 22.86-422.91 nm, average 91.99 nm) compared with WT, bgn-deficient, and dcn-deficient animals. In addition, fibrils were markedly less tightly packed with wide interfibrillar spaces, and fibril cross-sectional profiles often were ragged or notched but still predominantly circular.
Double-deficient animals exhibited a striking and early appearing gross skeletal phenotype (Fig. 6). Long bones were shorter and wider compared with WT animals and markedly osteopenic on X-ray and histological and SEM analysis. At 2 months of age, when osteopenia is barely discernible in bgn-deficient animals,(20) cortical and trabecular bone mass clearly was reduced severely in double-deficient animals compared with WT animals (BV/TV%, mean ± SD: double-KO mice, 1.61 ± 0.12 and n = 3; WT, 8.39 ± 1.85 and n = 3). In bone, bgn and dcn double deficiency resulted in a striking change in collagen fibril shape and organization (Fig. 7). In single mutant animals, fibrils still were predominantly circular in cross-section (despite an irregular, ragged, or notched profile) and of an altered size. No circular cross-sectional profiles could be observed at all in double-deficient animals, and fibrils uniformly displayed a marked “serrated” appearance, with a variety of shapes merging in places with a true “hieroglyphic-like” morphology (as described in certain human EDSs and animal correlates thereof(26–32)). Interfibrillar space appeared to be widened in thin sections from samples routinely processed for EM, suggesting a reduction in overall collagen mass. Interestingly, the typical collagenous texture observed in normal bone by BSE imaging was completely lost in bones from double-deficient animals and replaced by a uniform, glassy appearance of the mineralized matrix in polished and coated samples (Fig. 7).
BGN is an important determinant of collagen fibril assembly in vivo
Fibrillar collagens constitute the bulk of all connective tissues and provide the basis for the tensile properties as well as the biomechanical support for optimal function of these tissues. Based on a number of in vitro observations, the assembly and structure of collagen fibrils have long been thought to be modulated via interaction of fibrillar collagens with a number of macromolecules, including different types of collagens, noncollagenous glycoproteins, and proteoglycans.(9–16,33,34) SLRPs are important members of thehost of potential collagen binders/regulators, and in vitro data supporting such a role are available for most, if not all, SLRPs. Direct in vivo evidence for a role of some SLRPs in regulation of collagen assembly has been offered by the recent development of mice deficient in dcn, lumican, and fibromodulin, three distinct members of the SLRPs family. In all of these animals, collagen fibril anomalies have been noted in different tissues.(18,19,35,36) An analysis of collagen fibrils in the osteopenic bgn-deficient mice, conversely, had not been conducted previously. The data reported in this study establish that bgn plays a critical role in the regulation of collagen architecture and structure in vivo. Bgn deficiency results in formation of collagen fibrils noted for an irregular profile, a broader-size range, and less tight packing. These changes are not restricted to the skeleton and are generalized to diverse type I collagen-rich connective tissues.
Similar and additive effects of bgn and dcn deficiency in the dermis
In different tissues, the effects of biglycan deficiency may either translate into a macroscopic phenotype (as in bone) or be apparent at the ultrastructural and histological level only, as in skin. Bgn deficiency produces collagen abnormalities and thinning of the dermis but does not convey overt skin fragility. Although the observed ultrastructural and histological changes do predict a subtle degree of skin fragility, bgn-deficient mice are not dermatosparactic. Their skin might prove less resilient on biomechanical testing and yet does not rupture on simple manipulation, as is the case in animals with spontaneous or experimental dermatosparaxis, including dcn-deficient mice. Thus, Bgn and dcn deficiency seem to produce similar ultrastructural and histological changes in the skin but only dcn deficiency is apparently effective in inducing a dermatosparaxis-like phenotype. A macroscopically apparent effect implies a more severe impact on matrix organization than changes detected by EM or histology only. The greater impact of dcn deficiency versus bgn deficiency on skin integrity thus remains consistent with the greater relative abundance of dcn in the dermis, whereas the similarity in ultrastructural changes produced by either type of SLRP deficiency is consistent with an overall similar role of bgn and dcn in interactions with dermal collagen. In agreement with this interpretation, the effects of double-bgn and -dcn deficiency, as observed in the double-KO mice, are additive. In these animals, ultrastructural changes in dermal collagen are more pronounced than in either single mutant animals and extensive ruptures of the skin are produced even by gentle manipulation.
Distinct and synergic effects of bgn and dcn deficiency in bone
Although both bgn and dcn deficiency affect collagen fibril size and shape in bone, they do so in a markedly different and, in fact, opposite way. Fibril average diameter and size range increase as an effect of bgn deficiency and decrease as an effect of dcn deficiency, compared with WT animals. Because dcn deficiency results in larger fibrils in the dermis (and tendon), the effects of dcn deficiency on collagen fibril structure in bone seem to be rendered distinct and specific by the local matrix environment. Although the cutaneous phenotypes of bgn- and dcn-deficient mice are grossly distinct but histologically and ultrastructurally similar to one another, the skeletal phenotypes of bgn- and dcn-deficient mice differ from one another at all levels of investigation. Dcn-deficient mice do not feature the osteopenia of bgn-deficient mice either at the gross or at the histological level and exhibit distinct ultrastructural changes in bone collagen fibrils. Double-deficient mice display a unique ultrastructural phenotype in bone, noted for the almost complete loss of fibril basic geometry. Very few fibrils in the double-KO mice exhibit a predominantly circular cross-sectional profile, and the vast majority of the fibrils provide a noted example of the so-called “serrated” fibril morphology observed in many human disorders, first and foremost the varied spectrum of EDSs.(26–30) In the bone matrix of double-KO mice, the cross-sectional profile of collagen fibrils approaches the hieroglyphic-like pattern described for skin collagen in human dermatosparaxis and makes it hard to determine and measure their diameter. This ultrastructural phenotype is matched by a markedly osteopenic gross phenotype, which compared with the phenotype of bgn single-deficient mice is more severe and appears at an earlier animal age. Thus, dcn deficiency synergizes with bgn deficiency in producing a skeletal phenotype although the effects of individual dcn and bgn deficiencies in bone are quite distinct.
Finally, further studies are desirable to clarify the mechanisms by which the effects of bgn and dcn deficiency are similar and additive in the dermis and distinct and synergic in bone. Either the unique complement of other noncollagenous proteins found in both tissues or tissue-specific features of type I collagen or differences in the ratios of type I, type III, and type V collagen might reflect in diverse tissue-specific collagen-SLRP interaction and in tissue-specific effects of their disruption.
Relationship to human EDSs
Previously, the similarity between the cutaneous phenotype of the dcn-deficient mice with the cutaneous expression of human EDSs and relevant animal correlates has been noted.(18) Human EDSs comprise a markedly heterogeneous group of disorders, in which clinical heterogeneity reflects the varied expressivity in different tissues of multiple genetic defects, most of which involve collagen type I genes.(37) Changes in collagen fibrils occurring in human EDSs (variability in size and density, ragged profiles, “serrated” fibrils, and twisted fibrils) are closely similar to those observed in mice deficient in bgn, dcn, and other SLRPs. In addition to skin laxity or fragility, joint laxity and vascular fragility also characterize, clinically, certain EDSs. Curiously, all these cardinal elements of the EDSs as a group also have been reproduced by a spectrum of mouse models of SLRP deficiencies, including skin fragility,(18,19) joint laxity,(38) and vascular fragility (our unpublished data). The original analogy between murine decorin deficiency(18) and human cutaneous ED now can be broadened and reasonably elaborated as a working hypothesis in a more general paradigm, in which multiple forms of human EDSs and multiple murine models of SLRP deficiency may be inscribed. However, most ED variants are not recognized generally as typically associated with an overt skeletal pathology. This would leave the osteopenic biglycan-deficient animals (both the bgn KO model and the bgn/dcn double-KO model) outside of the envisioned paradigm. However, there have been repeated indications for variable degrees of osteopenia in patients with EDSs.(39) Furthermore, osteopenia is a recognized integral part of one specific subtype of human EDS (the progeroid variant, OMIM 130070). This rare disorder is the phenotypic consequence of a defective gene encoding xylosylprotein 4-β-galactosyltransferase I,(40,41) resulting in the production of BGN and DCN core proteins with a deficiency of GAG chain attachment. In this EDS variant, osteopenia is in fact observed in conjunction with growth failure, skin fragility, and cutaneous changes resembling those observed in progeria. Of note, skin fragility and growth failure are observed in the dcn/bgn double-KO mice. These mice also show a distinctive atrophy of the subcutis, which in humans represents the hallmark of true progeria that is mimicked in the progeroid variant of EDS. Thus, it seems reasonable to propose that depletion of both dcn and bgn in the double-KO mice results in a murine model of a human condition in which GAG-deficient DCN and BGN are produced, and a combined deficiency of both glycosylated BGN and glycosylated DCN occurs. If so, one would infer that either the stabilization or the interaction properties of DCN and BGN would indeed be dependent on efficient GAG attachment.
It is important to note, from a general point of view that all other known mutations underlying human EDSs occur in genes encoding either collagen chains (types I, III, and V) or collagen-processing enzymes (N-propeptidase and lysyl-hydroxylase).(37) Marked alterations in the organization of collagenous matrices result from these mutations and mediate the disease phenotypes. However, collagen is not the only determinant of the overall organization of collagenous matrices. As emphasized by our data and those of others, SRLP deficiencies obviously generate changes in the organization and structure of collagen fibrils, which translate into abnormal phenotypes reminiscent of various EDS-like conditions. Because not all human EDSs necessarily reflect mutations in collagen genes and the gene defect underlying certain variants remain unknown, SLRP-encoding genes emerge as potential candidate genes for subsets of human EDSs or related conditions, which remain to be identified.(30)
This work was supported in part by grants from the Ministry for University and Research (MIUR), Italy (to P.B.).
- 11983 Proteoglycans of developing bone. J Biol Chem 258:6588–6594., , , , , , , , ,
- 21989 Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J Biol Chem 264:4571–4576., ,
- 31998 Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 17:1–19., ,
- 41998 Matrix proteoglycans. From molecular design to cellular function. Ann Rev Biochem 67:609–652.
- 51995 The X-chromosomal human biglycan gene BGN is subject to X inactivation but is transcribed like an X-Y homologous gene. Hum Genet 96:44–52., , , , , , , , ,
- 61994 Selective inactivity of TGF-beta/decorin complexes. FEBS Lett 353:243–245., , , ,
- 71989 Proteoglycans in cell regulation. J Biol Chem 264:13369–13372.
- 81999 The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 274:18843–18846.
- 91987 The effect of proteoglycans on the morphology of collagen fibrils formed in vitro. Coll Relat Res 7:105–114.,
- 101993 Binding of fibromodulin and decorin to separate sites on fibrillar collagens. J Biol Chem 268:27307–27312.,
- 111993 Regulation of corneal collagen fibrillogenesis in vitro by corneal proteoglycan (lumican and decorin) core proteins. Exp Eye Res 56:635–648., ,
- 121994 Biosynthesis and interactions of small chondroitin/dermatan sulphate proteoglycans. Eur J Clin Chem Clin Biochem 32:259–264., , ,
- 131995 Decorin-type I collagen interaction. Presence of separate core protein- binding domains. J Biol Chem 270:8877–8883., , ,
- 141995 Interaction of biglycan with type I collagen. J Biol Chem 270:2776–2783., , , , ,
- 151996 Collagen fibril formation. Biochem J 316:1–11., , ,
- 161997 Increased diameters of collagen fibrils precipitated in vitro in the presence of decorin from various connective tissues. Connect Tissue Res 36:287–296.,
- 171990 Expression and localization of the two small proteoglycans biglycan and decorin in developing human skeletal and non-skeletal tissues. J Histochem Cytochem 38:1549–1563., , , ,
- 181997 Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 136:729–743., , , , ,
- 191998 Lumican regulates collagen fibril assembly: Skin fragility and corneal opacity in the absence of lumican. J Cell Biol 141:1277–1286., , , , ,
- 201998 Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 20:78–82., , , , , , , , , , , , , , ,
- 211984 Basic and “special” stains for plastic sections in bone marrow histopathology, with special reference to May-Grunwald Giemsa and enzyme histochemistry. Basic Appl Histochem 28:265–279., ,
- 221999 Osteoconduction in large macroporous hydroxyapatite ceramic implants: Evidence for a complementary integration and disintegration mechanism. Bone 24:579–589., , , ,
- 231995 Standards for mineral quantitation of human bone by analysis of backscattered electron images. Scanning 17(Suppl V):6–7., ,
- 241998 Mean atomic number and backscattered electron coefficient for some materials with low atomic mean number. Scanning 20:35–40., ,
- 251998 Monte Carlo simulation of electron backscattering from compounds with low mean atomic number. Scanning 20:45–49.,
- 261982 Structural abnormalities in the dermal collagen and elastic matrix from the skin of patients with inherited connective tissue disorders. J Invest Dermatol 79:7S–16S.,
- 271984 Dermal changes in Ehlers-Danlos syndrome. Clin Genet 25:477–484., ,
- 281993 The Ehlers-Danlos Syndrome. In: RoycePM, SteinmannB (eds.) Connective Tissue and Its Heritable Disorders. Molecular, Genetic and Medical Aspects. Wiley-Liss, Inc., New York, NY, USA, pp. 351–408., ,
- 291994 Differential ultrastructural aberrations of collagen fibrils in Ehlers-Danlos syndrome types I-IV as a means of diagnostics and classification. Hum Genet 93:394–407.,
- 302001 The Ehlers-Danlos syndrome: On beyond collagens. J Clin Invest 107:1063–1069.,
- 311988 An inherited connective tissue disease in the horse. Lab Invest 59:253–262., , , , , ,
- 321993 Abnormalities of collagen fibrils in a rabbit with a connective tissue defect similar to Ehlers-Danlos syndrome. Res Vet Sci 55:346–350., ,
- 331990 Collagen fibrillogenesis in vitro: Interaction of types I and V collagen regulates fibril diameter. J Cell Sci 95:649–657., , , ,
- 341990 Type I and type III collagen interactions during fibrillogenesis. Ann NY Acad Sci 580:161–175., , , ,
- 351999 Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J Biol Chem 274:9636–9647., , , , ,
- 362000 Differential expression of lumican and fibromodulin regulate collagen fibrillogenesis in developing mouse tendons. J Cell Biol 151:779–788., , , ,
- 371998 Ehlers-Danlos syndromes revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 77:31–37., , , ,
- 382000 Biglycan and fibromodulin double knockout mice develop ectopic sesamoid bones and premature osteoarthritis in the knee joint. J Bone Miner Res 15:S1;185., , , , , ,
- 391998 Assessment of bone in Ehlers Danlos syndrome by ultrasound and densitometry. Ann Rheum Dis 57:630–633., , ,
- 401987 Glycosaminoglycan-free small proteoglycan core protein is secreted by fibroblasts from a patient with a syndrome resembling progeroid. Am J Hum Genet 41:436–453., , , , , ,
- 411990 A genetic defect in the byosinthesis of dermatan sulfate proteoglycan. Galactosyltransferase I deficiency in fibroblasts from a patient with a progeroid syndrome. Proc Natl Acad Sci USA 87:1342–1346., , ,